March 6, 2015
The FDA has approved Cresemba to treat adults with invasive aspergillosis and invasive mucormycosis.
Cresemba (isavuconazonium sulfate, Astellas Pharma) is the sixth approved antimicrobial product that was designated as a qualified infectious disease product. This status is given to agents meant to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) Act. The FDA also granted isavuconazonium sulfate, available as an oral and intravenous formulation, orphan drug status.